Organon & Co. (OGN) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Organon & Co. Do?
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. (OGN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kevin Ali and employs approximately 10,000 people. With a market capitalization of $1.6B, OGN is one of the notable companies in the Healthcare sector.
Organon & Co. (OGN) Stock Rating — Reduce (April 2026)
As of April 2026, Organon & Co. receives a Reduce rating with a composite score of 42.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OGN ranks #2,486 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Organon & Co. ranks #312 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
OGN Stock Price and 52-Week Range
Organon & Co. (OGN) currently trades at $9.01. The stock gained $2.10 (30.4%) in the most recent trading session. The 52-week high for OGN is $15.85, which means the stock is currently trading -43.2% from its annual peak. The 52-week low is $6.16, putting the stock 46.4% above its annual trough. Recent trading volume was 39.5M shares, indicating strong institutional interest and high liquidity.
Is OGN Overvalued or Undervalued? — Valuation Analysis
Organon & Co. (OGN) carries a value factor score of 61/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 2.12x, compared to the Healthcare sector average of 23.63x — a discount of 91%. The price-to-book ratio stands at 2.12x, versus the sector average of 2.75x. The price-to-sales ratio is 0.25x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, OGN trades at 13.12x EV/EBITDA, versus 6.34x for the sector.
Overall, OGN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Organon & Co. Profitability — ROE, Margins, and Quality Score
Organon & Co. (OGN) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 99.9%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 5.8% versus the sector average of -33.1%.
On a margin basis, Organon & Co. reports gross margins of 55.6%, compared to 71.5% for the sector. The operating margin is 12.3% (sector: -66.1%). Net profit margin stands at 11.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -0.3% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
OGN Debt, Balance Sheet, and Financial Health
Organon & Co. has a debt-to-equity ratio of 1149.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.82x, suggesting adequate working capital coverage. Total debt on the balance sheet is $8.64B. Cash and equivalents stand at $672M.
OGN has a beta of 1.02, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Organon & Co. is 43/100, reflecting average volatility within the normal range for its sector.
Organon & Co. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Organon & Co. reported revenue of $6.29B and earnings per share (EPS) of $0.72. Net income for the quarter was $751M. Gross margin was 55.6%. Operating income came in at $780M.
In FY 2025, Organon & Co. reported revenue of $6.22B and earnings per share (EPS) of $0.72. Net income for the quarter was $187M. Gross margin was 53.3%. Revenue grew -2.9% year-over-year compared to FY 2024. Operating income came in at $425M.
In Q3 2025, Organon & Co. reported revenue of $1.60B and earnings per share (EPS) of $0.61. Net income for the quarter was $160M. Gross margin was 53.5%. Revenue grew 1.3% year-over-year compared to Q3 2024. Operating income came in at $243M.
In Q2 2025, Organon & Co. reported revenue of $1.59B and earnings per share (EPS) of $0.56. Net income for the quarter was $145M. Gross margin was 54.8%. Revenue grew -0.8% year-over-year compared to Q2 2024. Operating income came in at $229M.
Over the past 8 quarters, Organon & Co. has demonstrated a growth trajectory, with revenue expanding from $1.61B to $6.29B. Investors analyzing OGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
OGN Dividend Yield and Income Analysis
Organon & Co. (OGN) currently pays a dividend yield of 5.6%. At this yield, a $10,000 investment in OGN stock would generate approximately $$562.00 in annual dividend income. The net margin of 11.9% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.
OGN Momentum and Technical Analysis Profile
Organon & Co. (OGN) has a momentum factor score of 19/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.
OGN vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Organon & Co. (OGN) ranks #312 out of 838 stocks based on the Blank Capital composite score. This places OGN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing OGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OGN vs S&P 500 (SPY) comparison to assess how Organon & Co. stacks up against the broader market across all factor dimensions.
OGN Next Earnings Date
No upcoming earnings date has been announced for Organon & Co. (OGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy OGN? — Investment Thesis Summary
The quantitative profile for Organon & Co. suggests caution. The value score of 61/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 19/100, a headwind for near-term performance.
In summary, Organon & Co. (OGN) earns a Reduce rating with a composite score of 42.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OGN stock.
Related Resources for OGN Investors
Explore more research and tools: OGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OGN head-to-head with peers: OGN vs AZN, OGN vs SLGL, OGN vs VMD.